MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6

MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6

Background/Aims: Trastuzumab is an important treatment used for patients with Her-2-positive breast cancer, but an increasing incidence of trastuzumab resistance has been observed clinically during the past decade. Aberrant microRNA (miR) expression levels are correlated with prognosis and response...

Full description

Bibliographic Details
Main Authors: Xiangdong Lu, Jingjing Ma, Jiahui Chu, Qing Shao, Yao Zhang, Guangping Lu, Jun Li, Xiang Huang, Wei Li, Yongfei Li, Yang Ling, Tao Zhao
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2017-12-01
Series:Cellular Physiology and Biochemistry
Subjects:
Her-2-positive breast cancer
Trastuzumab resistance
MiR-129-5p
RpS6
Online Access:https://www.karger.com/Article/FullText/486122

Internet

https://www.karger.com/Article/FullText/486122

Similar Items